Drug Type in vivo CAR-T therapy |
Synonyms UB VV310 |
Target |
Mechanism CD20 modulators(B-lymphocyte antigen CD20 modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization Umoja Biopharma, Inc.Startup |
Active Organization Umoja Biopharma, Inc.Startup |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Non-Hodgkin Lymphoma | Preclinical | US | Umoja Biopharma, Inc.Startup | 07 Sep 2024 |
Autoimmune Diseases | Preclinical | US | Umoja Biopharma, Inc.Startup | 22 Sep 2023 |